Orthocell (OCC) H1 2025 earnings summary

Executive summary

• Revenue for the half-year ended 31 December 2024 increased 31% year-over-year to $4.3 million, driven by rapid market penetration of core products and international expansion.

• Key milestones included first international regulatory approval and sales of Remplir in Singapore, submission of a US FDA 510(k) application, and expanded distribution of Striate+ in Canada and the EU.

• A $17 million placement was completed to fund the US launch of Remplir and further growth, strengthening the balance sheet.

Financial highlights

• Net loss after tax for the half-year was $1,296,080, a significant improvement from a $5,230,035 loss in the prior year period.

• Cash and cash equivalents at 31 December 2024 were $30,842,790, up from $20,614,440 at 30 June 2024.

• Gross profit rose to $1,145,358 from $600,315 year-over-year.

• Striate+ revenue grew 42% and Remplir revenue grew 118% compared to the same period last year.

• Operating cash outflow was $5,616,059, compared to $4,781,721 in the prior year.

Outlook and guidance

• Anticipates US FDA clearance for Remplir in late March or early April 2025, with sales to commence shortly after.

• Expects continued and accelerated quarter-on-quarter revenue growth with additional international launches and regulatory approvals underway.

• Focus remains on de-risking by targeting significant and immediate market opportunities and leveraging strong cash reserves.